Artificial Intelligence
Independence Holding Company Announces 2020 Second-Quarter and Six-Month Results
STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) — Stamford, Connecticut, August 6, 2020. Independence Holding Company (NYSE: IHC) today reported 2020 second-quarter and six-month results.
Financial Results
Net income of $421,000, or $.03 per share for the three months ended June 30, 2020 compared to $6,847,000 or $.46 per share, diluted, for the three months ended June 30, 2019. Net income was $4,699,000 or $.32 per share, diluted, for the six months ended June 30, 2020 compared to $15,574,000 or $1.04 per share, diluted, for the six months ended June 30, 2019.
Net income in 2020 is lower primarily because of the following two factors. First, we have experienced a material increase in expenses related to the significant increase in hiring, licensing and training a large number of call center agents, all of whom are employees, and in connection with the recent acquisition of a marketing technology (“MarTech”) company. Currently, we have 143 call center agents primarily selling senior products, but do not yet have any meaningful sales from these new agents. This scaling up of expenses will continue until the 2021 Annual Enrollment Period (AEP) begins, which is when we will realize a large majority of our senior sales for the year. Beginning with AEP, which commences October 15, 2020, we expect to realize profits and reap the benefits of this ramp up. Second, we were affected by two non-recurring items: (i) 2020 net income includes expenses of $3,660,000, or $.25 per share, diluted, for compliance with the regulatory settlement agreements with our three insurance carriers resulting from a multistate market conduct examination with respect to several of our specialty health products for the period January 1, 2014 through September 30, 2017, and (ii) the 2019 six months’ net income includes a $2.6 million gain, net of tax, or $.17 per share, diluted, on the sale of an equity method investment with no corresponding gain this year.
On July 28, 2020, the United States Court of Appeals for the Seventh Circuit affirmed the District Court’s confirmation of an arbitration award in favor of the Company. As previously disclosed, the Company was awarded $5,641,000 in an arbitration proceeding against a third party administrator with which we formerly did business (“TPA”). The TPA filed a bond for the awarded amount in order to proceed. IHC has not yet recorded this award, and only upon final determination will IHC be able to recognize the award in its earnings.
The Company reported revenues of $107,305,000 for the three months ended June 30, 2020 compared to revenues for the three months ended June 30, 2019 of $95,122,000. The Company reported revenues of $211,302,000 for the six months ended June 30, 2020 compared to revenues for the six months ended June 30, 2019 of $189,304,000. The increase in revenues primarily relates to an increase in rates for the Paid Family Leave business and higher premium volume in our pet insurance business
Chief Executive Officer’s Comments
Roy T. K. Thung, Chief Executive Officer, commented, “Although net income is lower for 2020 due to the reasons stated above and sales of certain products would have been higher if not for the COVID-19 pandemic, we are pleased with our sales and underwriting results for the first six months of 2020. We have implemented business continuity and emergency response plans to continue to provide service to our customers and to protect the health and wellbeing of our employees whether they are working from home or once they return to offices that have been modified to protect them. Our customer facing agents have transitioned to a full-time work at home model, and with the implementation of enhanced technology solutions, we have not identified any material impact to agent productivity. In fact, our accelerated deployment of technology improvements in the areas of training, CRM, and prospect scoring, has positioned us to gain efficiencies during the upcoming annual enrollment periods. Once agents are able to return to work, we expect to continue to allow some agents to work remotely. The success we are currently experiencing with the work-from-home model will allow us to significantly ramp up the number of agents by the 2021 and 2022 AEPs, and our MarTech platform can be readily scaled to supply all of the necessary leads.
Mr. Thung continued, “We are particularly excited by the prospects for two of our lines of business: pet insurance and senior market sales. I would like to first update you on the prospects of our pet division. We continue to see very strong demand for pet insurance resulting from record adoptions and breeder sales as pet parents are seeking the comfort of dog and cat companions in these difficult times. To this end, Pet Partners, Inc. (PPI) continues to experience a significant increase in sales as a result of increased registrations with its exclusive relationship with American Kennel Club (AKC) and PPI’s efforts to increase insurance conversions through enhanced technology and direct marketing. PPI has developed an app with state-of-the-art technology (including a full suite of insurance self-service capabilities), which will be available in Android and IOS app stores by September 1st. We will distribute this app with current sales channels and market it through other large partners that want to distribute pet insurance to their clients. This app will also contain features that we believe will be very attractive to AKC breeders and pet parents who wish to remain in touch with their breeder and litter mates. PPI is also coming to market with several white label distribution deals and has significantly increased its investment in marketing outreach to pet parents under the PPI brand. We believe these initiatives will continue to accelerate PPI’s insured pets. Our other pet distributors continue to show accelerating growth as they move business to one of our carriers, Independence American Insurance Company (IAIC). We now believe we will exceed $100 million of gross annualized pet insurance premium or over 170,000 pet lives by the end of this year, and will be significantly higher by the end of 2021.
We have invested a considerable amount of capital entering the senior market. We have enhanced our SalesForce CRM platform, as well as our producer licensing, consumer and web-based enrollment systems. We continue to build our MarTech infrastructure through artificial intelligence data science, and automated remarketing among other capabilities to generate high-intent leads. In conjunction with continuously increasing our proficiency in efficiently generating leads, we are actively working to hire, train and license additional senior-focused customer care center agents. We currently have 143 licensed agents focused primarily on the senior market, and we are striving to have 200 agents by the 2021 AEP, which commences October 15, 2020. In addition, IAIC has approval of its Medicare Supplement product in twenty-nine states, and expect to add a 30th state by the 2021 AEP. This will be a compelling proprietary product offering in our impressive portfolio of senior products.
In conclusion, while we have made significant investments in growing these two lines of business which has impacted quarterly earnings, we strongly believe that we have created significant shareholder value. We have the necessary tools in place for material growth in the senior and pet markets, which will benefit us in the fourth quarter and in the future.”
Mr. Thung added, “IHC has a very strong balance sheet with no indebtedness and a very substantial amount of free cash at the corporate level and significant excess capital in our insurance companies. Our book value was $31.23 per share at June 30, 2020. IHC increased its annual dividend to $.44 per share in 2020, which is the sixth increase since December 2014 when the annual dividend paid to the stockholders was $.07 per share. Our overall investment portfolio continues to be very highly rated (on average, AA) and has an effective duration under three years. In May 2020, the Company repurchased 36,377 shares of IHC common stock in connection with a tender offer to its stockholders by permitting them the opportunity to tender shares of IHC common stock for cash. Year to date the Company has repurchased 200,110 shares including the aforementioned tender offer and is still repurchasing shares on a daily basis up to the maximum allowable, so as to provide liquidity to the market.”
About The IHC Group
Independence Holding Company (NYSE: IHC), formed in 1980, is a holding company that is principally engaged in underwriting, administering and/or distributing group and individual specialty benefit products, including disability, supplemental health, pet, and group life insurance through its subsidiaries (Independence Holding Company and its subsidiaries collectively referred to as “The IHC Group”). The IHC Group consists of three insurance companies (Standard Security Life Insurance Company of New York, Madison National Life Insurance Company, Inc. and Independence American Insurance Company). We also own the following agencies: (i) PetPartners, Inc., our pet insurance administrator; (ii) IHC Specialty Benefits, Inc., a technology-driven full-service marketing and distribution company that focuses on small employer and individual consumer products through its call center, career agents, and Independence Brokerage Group; and (iii) The INSX Cloud Platform through My1HR, our wholly owned Web Based Entity. Our InsureTech division is comprised of our call centers, field and career agents, in-house MarTech artificial intelligence capabilities and domains, including www.healthedeals.com; www.healthinsurance.org; www.medicareresources.org; www.petplace.com; and www.mypetinsurance.com.
Forward-looking Statements
Certain statements and information contained in this release may be considered “forward-looking statements,” such as statements relating to management’s views with respect to future events and financial performance. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, economic conditions in the markets in which IHC operates, new federal or state governmental regulation, IHC’s ability to effectively operate, integrate and leverage any past or future strategic acquisition, and other factors which can be found in IHC’s other news releases and filings with the Securities and Exchange Commission. IHC expressly disclaims any duty to update its forward-looking statements unless required by applicable law.
INDEPENDENCE HOLDING COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
June 30, 2020
(In Thousands, Except Shares and Per Share Data)
Three Months Ended | Six Months Ended | |||||||||||
June 30, | June 30, | |||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||
REVENUES: | ||||||||||||
Premiums earned | $ | 98,691 | $ | 84,947 | $ | 194,741 | $ | 167,736 | ||||
Net investment income | 3,139 | 4,134 | 6,379 | 8,130 | ||||||||
Fee income | 4,248 | 3,707 | 8,190 | 7,895 | ||||||||
Other income | 652 | 879 | 1,129 | 4,563 | ||||||||
Net investment gains | 575 | 1,455 | 863 | 1,626 | ||||||||
Net impairment losses recognized in earnings | – | – | – | (646 | ) | |||||||
107,305 | 95,122 | 211,302 | 189,304 | |||||||||
EXPENSES: | ||||||||||||
Insurance benefits, claims and reserves | 54,589 | 44,410 | 108,647 | 87,529 | ||||||||
Selling, general and administrative expenses | 51,979 | 42,206 | 96,553 | 82,735 | ||||||||
106,568 | 86,616 | 205,200 | 170,264 | |||||||||
Income before income taxes | 737 | 8,506 | 6,102 | 19,040 | ||||||||
Income taxes | 199 | 1,590 | 1,242 | 3,234 | ||||||||
Net income | 538 | 6,916 | 4,860 | 15,806 | ||||||||
(Income) from noncontrolling interests | (117 | ) | (69 | ) | (161 | ) | (232 | ) | ||||
NET INCOME ATTRIBUTABLE TO IHC | $ | 421 | $ | 6,847 | $ | 4,699 | $ | 15,574 | ||||
Basic income per common share | $ | .03 | $ | .46 | $ | .32 | $ | 1.04 | ||||
WEIGHTED AVERAGE SHARES OUTSTANDING | 14,765 | 14,929 | 14,811 | 14,939 | ||||||||
Diluted income per common share | $ | .03 | $ | .46 | $ | .32 | $ | 1.04 | ||||
WEIGHTED AVERAGE DILUTED SHARES OUTSTANDING | 14,767 | 14,948 | 14,839 | 15,007 | ||||||||
As of August 3, 2020, there were 14,668,481 common shares outstanding, net of treasury shares.
INDEPENDENCE HOLDING COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands)
June 30, | December 31, | |||||||||||
2020 | 2019 | |||||||||||
ASSETS: | ||||||||||||
Investments: | ||||||||||||
Short-term investments | $ | 1,149 | $ | 50 | ||||||||
Securities purchased under agreements to resell | 101,417 | 107,157 | ||||||||||
Fixed maturities, available-for-sale | 384,245 | 384,974 | ||||||||||
Equity securities | 3,449 | 3,747 | ||||||||||
Other investments | 11,327 | 15,208 | ||||||||||
Total investments | 501,587 | 511,136 | ||||||||||
Cash and cash equivalents | 21,224 | 21,094 | ||||||||||
Due and unpaid premiums | 34,497 | 26,244 | ||||||||||
Due from reinsurers | 359,244 | 362,969 | ||||||||||
Goodwill | 75,949 | 60,165 | ||||||||||
Other assets | 88,792 | 72,695 | ||||||||||
TOTAL ASSETS | $ | 1,081,293 | $ | 1,054,303 | ||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY: | ||||||||||||
LIABILITIES: | ||||||||||||
Policy benefits and claims | $ | 179,777 | $ | 164,802 | ||||||||
Future policy benefits | 199,775 | 201,205 | ||||||||||
Funds on deposit | 141,597 | 140,951 | ||||||||||
Unearned premiums | 21,601 | 7,282 | ||||||||||
Other policyholders’ funds | 11,646 | 12,049 | ||||||||||
Due to reinsurers | 3,640 | 5,016 | ||||||||||
Accounts payable, accruals and other liabilities | 61,569 | 61,049 | ||||||||||
TOTAL LIABILITIES | 619,605 | 592,354 | ||||||||||
Commitments and contingencies | ||||||||||||
Redeemable noncontrolling interest | 2,364 | 2,237 | ||||||||||
STOCKHOLDERS’ EQUITY: | ||||||||||||
Preferred stock (none issued) | – | – | ||||||||||
Common stock | 18,625 | 18,625 | ||||||||||
Paid-in capital | 123,804 | 122,717 | ||||||||||
Accumulated other comprehensive income | 2,854 | 1,212 | ||||||||||
Treasury stock, at cost | (74,325 | ) | (69,724 | ) | ||||||||
Retained earnings | 388,317 | 386,864 | ||||||||||
TOTAL IHC STOCKHOLDERS’ EQUITY | 459,275 | 459,694 | ||||||||||
NONREDEEMABLE NONCONTROLLING INTERESTS | 49 | 18 | ||||||||||
TOTAL EQUITY | 459,324 | 459,712 | ||||||||||
TOTAL LIABILITIES AND EQUITY | $ | 1,081,293 | $ | 1,054,303 | ||||||||
CONTACT: Loan Nisser
(646) 509-2107
www.IHCGroup.com
Artificial Intelligence
Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 30, 2024 /PRNewswire/ — The report titled “Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.
“Global Expansion and Technological Advancements in Analytics Services”
Clinical trial analytics services are revolutionizing the landscape of medical research and drug development across the globe by utilizing cutting-edge data analytics and statistical methodologies to offer invaluable insights from clinical trial data. These services enhance trial efficiency, streamline costs, and boost accuracy, enabling stakeholders to refine study protocols, improve patient recruitment measures, ensure participant safety, and conduct in-depth effectiveness studies. Such analytics are pivotal in supporting clinical development strategies, facilitating smoother regulatory approvals, and aiding in ongoing market surveillance and informed decision-making. Challenges such as data privacy concerns and the substantial investments required, the sector continues to grow, driven by an increasing focus on advancing drug discoveries and the sheer volume of clinical trials. The Americas lead the market with robust clinical trial activity, supported by Europe’s push for more transparent and unified trial regulations. Meanwhile, the Middle East is emerging as a key player with significant healthcare investments, and the Asia Pacific region is recognized for its cost advantages and substantial patient demographics, becoming an attractive locale for clinical research organizations (CROs) and pharmaceutical advancements. This global momentum towards personalized medicine and heightened technology integration signifies a promising future for clinical trial analytics services in enhancing the efficacy and outcomes of clinical trials worldwide.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Revolutionizing Clinical Trials through Analytics: A New Era in Drug Discovery”
The pharmaceutical market is witnessing a significant transformation, marked by an increased focus on developing treatments for a broader spectrum of diseases, including those once deemed untreatable. This shift has propelled the expansion of clinical trials, which are now more complex due to advanced technologies, the inclusion of varied patient demographics, and stringent regulatory standards. As a result, managing and analyzing the vast amounts of data from these clinical trials has become a daunting task. Enter clinical trial analytics services, a game-changing solution that streamlines the management of these trials. These services offer indispensable insights for making strategic decisions, facilitating patient recruitment, ensuring regulatory compliance, and evaluating market potential, ultimately speeding up the delivery of new therapies. With the pharmaceutical sector’s deep investment in the quest for innovative treatments, the pivotal role of clinical trial analytics services in enhancing efficiency and driving success in drug development is clearer than ever.
“Revolutionizing Drug Development: The Power of Clinical Data Analytics”
Clinical data analytics plays a pivotal role in transforming drug development by meticulously analyzing information gathered during clinical trials. This process is key to unlocking valuable insights that lead to better clinical decisions, enhanced trial efficiency, and faster path to market for new treatments. It effectively decodes patterns, forecasts results, and elevates patient care by watching over potential adverse impacts closely. The compilation of a wide variety of data, ranging from patient demographics, clinical outcomes, to biomarkers, underpins these analytics. Innovative technologies including machine learning and artificial intelligence are at the forefront of dissecting these complex data sets to offer understandable insights. The cornerstone of this endeavor is maintaining supreme data quality, ensuring the conclusions drawn are solid and dependable. Clinical trial data management plays an instrumental role, orchestrating the collection, integration, and validation of data throughout its lifecycle. This meticulous process involves designing data capturing systems, setting standards for data collection, and closely monitoring to uphold the integrity of data. Additionally, the blueprinting and vigilant monitoring of clinical trials are critical, demanding clear goals, precise sample sizes, and thorough oversight to guarantee trial integrity and participant safety. Engaging patients in the trial process further underscores the focus on patient-centered approaches, ensuring trials are not just about data but also about the individuals who make the research possible.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“IQVIA Inc. at the Forefront of Clinical Trial Analytics Services Market with a Strong 10.57% Market Share”
The key players in the Clinical Trial Analytics Services Market include Laboratory Corporation of America Holdings, SGS S.A., QIAGEN N.V., ICON PLC, IQVIA Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trial Analytics Services Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Analytics Services Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trial Analytics Services Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Dive into the Clinical Trial Analytics Services Market Landscape: Explore 184 Pages of Insights, 574 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trial Analytics Services Market, by ServicesClinical Trial Analytics Services Market, by ComponentClinical Trial Analytics Services Market, by StagesClinical Trial Analytics Services Market, by End-UserClinical Trial Analytics Services Market, by DeploymentAmericas Clinical Trial Analytics Services MarketAsia-Pacific Clinical Trial Analytics Services MarketEurope, Middle East & Africa Clinical Trial Analytics Services MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030In Silico Clinical Trials Market – Global Forecast 2024-2030Clinical Trial Supplies Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-analytics-services-market-projected-to-reach-11-95-billion-by-2030—exclusive-report-by-360iresearch-302131960.html
Artificial Intelligence
Synthetik Applied Technologies LLC announces development of UrbanScale – a modeling platform for the prediction, characterization, and quantification of extreme urban heat
AUSTIN, Texas and LONDON, April 30, 2024 /PRNewswire/ — Synthetik Applied Technologies announces the development of UrbanScale, a tool to model and predict effects of extreme heat in urban areas, through a project funded by the National Oceanic and Atmospheric Association (NOAA). The physical characteristics of urban areas amplify heat effects resulting in what are known as urban heat islands — areas where surface temperatures are much higher than their surroundings. The UrbanScale tool addresses this climate peril with sophisticated analytic tools based on physics informed neural networks and cutting-edge machine learning to predict urban heat and help better understand and mitigate the risks associated with these extreme heat events. As a result of climate change, these events are expected to increase, impacting both the people that live in urban areas and the infrastructure on which they depend.
The UrbanScale platform shows significant promise to provide data on the severity of heat islands and their effects to better understand how they impact human health, energy use and damage to physical infrastructure. This information will provide a step-change in capability for government agencies, urban planners, and transportation authorities to direct efforts for mitigation and intervention. In particular, inclusion of demographic information into data pipelines will allow understanding of how urban heat effects may impact vulnerable or disadvantaged populations. Integration with climate forecasts and models will also provide unprecedented capabilities for forecasting risk associated with climate change.
Josh Hatfield, Director of Research and Development at Synthetik, said:
‘We are extremely grateful for the opportunity to study such an important issue. Extreme heat is already the largest cause of weather-related fatalities in the US, and climate change will only increase the importance of understanding heat in urban environments. Helping to meet that challenge fits directly into Synthetik’s mission.’
Synthetik COO Tim Brewer commented:
‘The UrbanScale tool will allow both our government and insurance partners to better characterize the risk of extreme heat in urban centers and promises to deliver critical insight on the way these events impact energy demands. We look forward to exploring its wide-ranging applications.’
Synthetik plans further development of UrbanScale with NOAA and other partners in the public and private sector.
For all inquiries: Contact Synthetik Applied Technologies PR [email protected]
Logo – https://mma.prnewswire.com/media/2067510/Synthetik_Applied_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/synthetik-applied-technologies-llc-announces-development-of-urbanscale–a-modeling-platform-for-the-prediction-characterization-and-quantification-of-extreme-urban-heat-302132016.html
Artificial Intelligence
GLiNTECH – a Valiantys company, wins Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH declared Finalists for Team Excellence and ITSM Solutions
PARIS, April 30, 2024 /PRNewswire/ — Atlassian announced today that GLiNTECH – a Valiantys company has won the Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH were further declared finalists for the Team Excellence and ITSM Solutions awards, respectively.
This is an acknowledgement of their outstanding work for Atlassian customers during the calendar year 2023. This includes exceptional efforts in developing new business and driving innovative solutions for customer success.
“Our industry leading partners play a vital role in our customers’ continued success. We’re honored to highlight our top partners as award finalists this year, reflecting their ongoing commitment to delivering innovative solutions and unparalleled Atlassian services globally,” said Ko Mistry, Atlassian’s Head of Global Channels.
“We are delighted to be named as finalists for these awards from Atlassian, and we are particularly proud to celebrate GLiNTECH’s achievement in winning the Services (APAC) award.” said Emmanuel Benoit, Global Chief Executive Officer, Valiantys. “At Valiantys, embracing diversity of thought and challenging the ways our teams work has always provided Valiantys with a competitive edge to consistently deliver tangible results and value. We look to the future with unwavering determination and confidence as we continue to drive innovation and unlock potential for our customers around the globe.”
“We dedicate our IT Consulting Services and Custom Solutions to fulfilling our customers’ needs for success,” commented Dimitri Spyridopoulos, Chief Executive Officer GLiNTECH – a Valiantys company. “It’s an honor to be recognized by Atlassian as a finalist in two categories that reflect these efforts: Services and ITSM Solutions, and to be declared as winner for the Services award (APAC).”
For more information regarding this Press Release, contact: [email protected]
About Valiantys
Valiantys is a leading global consulting and services firm dedicated to Atlassian. The company accelerates business transformation by digitizing processes and modernizing teamwork, using the best agile methods and tools. Its Atlassian technical expertise is unparalleled and Valiantys supports its customers across the entire spectrum of projects on those platforms. As a recognized Agile at Scale, ITSM, and Cloud Specialized Partner, Valiantys help organizations accelerate time to value with Agile at scale, cloud, and ITSM implementations. Because teamwork requires more than just tools, the firm bridges the gap between applications and strategic practices such as SAFe® and ITIL. Over the last 15 years, Valiantys has helped more than 5,000 customers achieve their desired business outcomes at a reduced time to value, through improved team collaboration. More information about Valiantys can be found at https://www.valiantys.com/
About GLiNTECH – a Valiantys Company
GLiNTECH is a renowned Atlassian Platinum Partner headquartered in Australia and is the preferred choice for over 300 leading brands. The company has amassed more than 20 years of experience servicing enterprise clients across the Asia Pacific region, earning Atlassian Partner of the Year five times, including most recently for Professional Services. GLiNTECH is recognized as a Specialized Atlassian Cloud and ITSM partner. The company offers deep expertise in Licensing, Training, Support, Managed Services, Consulting, and Agile methodologies and has a proven record in providing reliable solutions while driving success within the Atlassian ecosystem. More information about GLiNTECH can be found here: https://www.glintech.com/
GLiNTECH was acquired by Valiantys in February 2024.
Photo – https://mma.prnewswire.com/media/2397508/GLiNTECH_2023_Services_award.jpg Logo – https://mma.prnewswire.com/media/1980997/Valiantys_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glintech—a-valiantys-company-wins-atlassian-partner-of-the-year-2023-services-apac-award-valiantys-and-glintech-declared-finalists-for-team-excellence-and-itsm-solutions-302127386.html
-
Uncategorized6 days ago
Cherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence5 days ago
Hikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days ago
HITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence5 days ago
Web O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Artificial Intelligence5 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence4 days ago
Cognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Uncategorized5 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry